USMLE Step 1 Glycogen Storage Diseases

Mastering the glycogen storage diseases (GSDs) is a high-yield task for USMLE Step 1, as it requires integrating foundational biochemistry with distinct clinical presentations. These enzyme defects transform abstract metabolic pathways into tangible patient scenarios, testing your ability to connect molecular dysfunction to physical findings. Your success hinges on recognizing the patterns that differentiate hepatic from myopathic forms and understanding the specific hypoglycemia clues that point to each diagnosis.

Foundational Framework: Hepatic vs. Myopathic GSDs

The first and most critical classification splits GSDs into two broad categories based on the primary tissue affected. This distinction directly dictates the patient's chief complaint and guides your diagnostic reasoning.

Hepatic GSDs primarily affect the liver, the body's central glucose reservoir. When glycogen cannot be properly broken down here, the result is systemic hypoglycemia, especially during fasting. These patients, often infants or young children, present with failure to thrive, hepatomegaly (a massively enlarged, firm liver), and episodes of profound low blood sugar leading to lethargy, seizures, or coma. The liver is full of glycogen it cannot liberate, like a locked pantry during a famine.

Myopathic GSDs primarily affect skeletal muscle. Since muscle uses glycogen for its own energy needs and does not release glucose into the bloodstream, these disorders do not cause hypoglycemia. Instead, patients experience exercise intolerance, muscle cramps, pain, and weakness with activity. They may present with myoglobinuria (dark urine) after strenuous exercise due to muscle breakdown. The defect here is in the local fuel supply for muscle contraction.

The Hepatic GSDs: Hypoglycemia and Hepatomegaly

The classic hepatic GSDs are defined by their enzyme defect within the glycogenolysis pathway, leading to the hallmark triad: fasting hypoglycemia, hepatomegaly, and growth failure.

Von Gierke Disease (GSD I) is caused by a deficiency in glucose-6-phosphatase. This is the final enzymatic step for the liver to release free glucose into the blood from either glycogen breakdown or gluconeogenesis. Because both pathways are blocked, patients suffer from severe fasting hypoglycemia. Unique laboratory findings include lactic acidosis (from shunting of glucose-6-phosphate into glycolysis), hyperlipidemia (especially triglycerides), and hyperuricemia (leading to gout). The latter results from increased ATP degradation and lactate competition for renal excretion of urate.

Cori Disease (GSD III) is a debranching enzyme deficiency. This enzyme has two activities: it transfers branches (oligo-$\alpha$1,4-$\alpha$1,4-glucantransferase) and then cleaves them (amylo-$\alpha$1,6-glucosidase). Its absence means glycogen can only be partially degraded, leaving behind a limit dextrin structure. Presentation resembles GSD I, but key differences emerge: hypoglycemia is less severe because gluconeogenesis remains intact, and muscle involvement is common (mixed hepatic-muscular form), leading to weakness. Elevated liver transaminases and creatine kinase (if muscle is involved) are clues.

Andersen Disease (GSD IV) is a defect in the branching enzyme, which normally introduces $\alpha$1,6 branches during glycogen synthesis. Without it, glycogen forms long, unbranched chains (amylopectin-like) that are insoluble and accumulate in tissues. This is primarily a hepatic disease but is fundamentally a storage disorder, not a breakdown one. It paradoxically causes cirrhosis and progressive liver failure, not hypoglycemia, as the abnormal glycogen damages hepatocytes. The liver is firm and cirrhotic, not just enlarged.

The Myopathic GSDs: Exercise Intolerance and Cramps

These diseases impair the muscle's ability to mobilize glycogen for its own anaerobic glycolysis during strenuous activity.

McArdle Disease (GSD V) results from a deficiency of muscle glycogen phosphorylase. Patients classically present with exercise intolerance, painful muscle cramps, and myoglobinuria within minutes of initiating intense activity (e.g., sprinting or lifting). A pathognomonic finding is the "second-wind" phenomenon: if they rest briefly at the onset of cramps, they can continue exercise at a slower pace, as they switch to using blood-borne fuels like fatty acids and glucose. The forearm ischemic exercise test shows a blunted rise in venous lactate.

Pompe Disease (GSD II) is caused by a deficiency of acid $\alpha$-1,4-glucosidase (acid maltase), a lysosomal enzyme. This is fundamentally different from other GSDs; it is a lysosomal storage disease, not a defect in cytoplasmic glycogen metabolism. Glycogen accumulates in lysosomes, disrupting cellular architecture. In the severe infantile form, it presents as a floppy infant with profound hypotonia, cardiomegaly (due to glycogen in cardiac muscle), macroglossia, and progressive cardiorespiratory failure, usually fatal within the first year. The adult-onset form presents with progressive proximal muscle weakness resembling limb-girdle muscular dystrophy.

Step 1 Strategies for Identification and Differentiation

Your exam will present these diseases within clinical vignettes. Your task is to connect the dots from the narrative to the underlying enzyme defect.

1. Start with the Tissue. Is the vignette about a chubby infant with a huge belly (hepatomegaly) and seizures after a missed meal (hypoglycemia)? Think hepatic GSDs. Is it about a young adult with cramps and dark urine after a workout? Think myopathic GSDs (McArdle). Is it about an infant who is "floppy" with a big heart? Think Pompe.

1. Use the Unique Metabolic Clues as Tie-Breakers. Within hepatic GSDs, lab values are your diagnostic key.

• Hypoglycemia + Lactic Acidosis + Hyperuricemia + Hypertriglyceridemia = Von Gierke (GSD I). This combination is virtually pathognomonic.
• Hypoglycemia + Elevated Transaminases + Possibly elevated CK = Cori (GSD III). The hypoglycemia is milder than in GSD I.
• Cirrhosis/Liver Failure in an Infant/Child without prominent hypoglycemia = Andersen (GSD IV).

1. Memorize the Cardinal Associations. For myopathic GSDs, rely on the classic presentations:

• Cramps + Myoglobinuria + "Second Wind" = McArdle (GSD V).
• Infantile Hypotonia + Cardiomegaly + Respiratory Failure = Infantile Pompe (GSD II). Recall that Pompe is the only GSD with significant heart involvement.

1. Visualize the Pathway. Mentally trace the glycogenolysis pathway. A defect early (phosphorylase in muscle = McArdle) stops the process entirely for that tissue. A defect at the final step (glucose-6-phosphatase = Von Gierke) blocks all hepatic glucose output. A defect in shaping the molecule (branching enzyme = Andersen) causes structural disease, not an energy crisis.

Common Pitfalls

1. Confusing Tissue Specificity: A classic trap is associating hepatomegaly with all GSDs. While true for hepatic forms, McArdle and Pompe do not cause significant hepatomegaly. Conversely, associating all muscle symptoms with elevated CK: Pompe disease often has a normal or only mildly elevated CK, especially in the infantile form, despite severe weakness.

1. Misattributing Hypoglycemia: Assuming all GSDs cause hypoglycemia is a critical error. Myopathic GSDs (II, V) do not cause systemic hypoglycemia because muscle glycogen is not used for blood glucose maintenance. Furthermore, Andersen disease (GSD IV) primarily causes cirrhosis, not hypoglycemia.

1. Overlooking Pompe's Unique Nature: Treating Pompe like other cytoplasmic GSDs leads to mistakes. Remember it is a lysosomal storage disease. This explains its different presentation (hypotonia, cardiomegaly) and its diagnosis via enzyme assay (like other lysosomal disorders) rather than purely metabolic testing.

1. Mixing Up Enzyme Functions: Confusing the debranching enzyme (Cori, breaks down glycogen) with the branching enzyme (Andersen, builds glycogen) is a frequent memory lapse. Use the names: "Debrancher" deficiency means it can't break down branches, so glycogen accumulates abnormally. "Brancher" deficiency means it can't build branches properly, leading to structurally abnormal, damaging glycogen.

Summary

• Classify first by tissue: Hepatic GSDs (I, III, IV) present with hypoglycemia and hepatomegaly; Myopathic GSDs (II, V) present with exercise intolerance, cramps, or weakness.
• Von Gierke (GSD I, glucose-6-phosphatase) is the classic hepatic disease with severe hypoglycemia, lactic acidosis, hyperuricemia, and hypertriglyceridemia.
• Pompe (GSD II, acid maltase) is a lysosomal disorder causing infantile hypotonia, cardiomegaly, and respiratory failure; it is the only GSD with significant heart involvement.
• Cori (GSD III, debranching enzyme) causes a mixed hepatic/muscular picture with hypoglycemia (less severe than GSD I) and possible muscle weakness.
• McArdle (GSD V, muscle phosphorylase) causes exercise-induced cramps, myoglobinuria, and the "second-wind" phenomenon.
• Andersen (GSD IV, branching enzyme) leads to cirrhosis and liver failure due to abnormal glycogen storage, not prominent hypoglycemia.
• For Step 1, use the clinical vignette's tissue focus and unique lab findings as a systematic algorithm to identify the specific enzyme defect.